For corporate, partnering or investor enquiries, please contact Cresaryn through the authorised enquiry channel.
Medical advice, adverse-event reports and patient-specific questions should not be submitted through this corporate website.
If an adviser-controlled transaction process is active, all acquisition and licensing enquiries may be redirected to the company’s appointed adviser.
Detailed scientific, commercial or transaction materials are available only to verified parties and may require a confidentiality agreement.
Media and unsolicited supplier enquiries should identify their organisation and purpose clearly.